ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Knockdown of caspase-activated DNase and B-cell lymphoma 2 inhibits cell proliferation and drug resistance in TP53-mutant multiple myeloma.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTP53 mutations are infrequently found in multiple myeloma (MM), a malignancy characterized by the clonal proliferation of plasma cells that secrete monoclonal immunoglobulin. This study explored the mechanism of caspase-activated DNase (CAD) and B-cell lymphoma 2 (BCL-2) in regulating proliferation and drug resistance of TP53-mutant MM cells.
methodsTP53 wild-type (H929) and TP53-mutant (U266 and RPMI-8226) MM cell lines were cultured under standard conditions. TP53-mutant cells were transfected with lentiviral shRNA plasmids targeting CAD and BCL-2 (Lv-sh-CAD and Lv-sh-BCL-2). Cell viability, proliferation, apoptosis, and cell cycle, as well as the levels of CAD, BCL-2, cell cycle-related proteins (P21, Cyclin D1, Cyclin-dependent kinase 1 [CDK1]) and drug resistance-associated proteins (adenosine triphosphate-binding cassette subfamily B member 1 [ABCB1], ABCG2) were assessed by CCK-8, colony formation, flow cytometry, qRT-PCR and western blot assays. A xenograft tumor model was established and treated with bortezomib for in vivo validation.
resultsCompared to H929 cells, U266 and RPMI-8226 cells exhibited elevated CAD and BCL-2 levels as well as reduced drug resistance. Knockdown of CAD or BCL-2 in TP53-mutant MM cells decreased cell proliferation, and the expression of ABCB1, ABCG2, Cyclin D1 and CDK1, while increasing apoptosis, G2/M arrest level and P21 expression. These changes also reduced resistance to bortezomib and doxorubicin. Co-knockdown of CAD and BCL-2 further promoted G2/M arrest, thereby inhibiting proliferation and drug resistance, and facilitating apoptosis. In vivo, co-knockdown of CAD and BCL-2 suppressed the growth of TP53-mutant MM cells and enhanced their sensitivity to bortezomib.
conclusionsCAD and BCL-2 were highly expressed in TP53-mutant MM cells, and their co-knockdown boosted G2/M cell cycle arrest, thereby preventing cell proliferation, enhancing apoptosis, and reducing drug resistance.
Indexed as
Identifiers
41504908What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.